M S Sajid1, M R S Siddiqui, B Kianifard, M K Baig. 1. Department of Colorectal Surgery, Worthing Hospital, Washington Suite, North Wing, Worthing, West Sussex BN11 2DH, UK. surgeon1wrh@hotmail.com
Abstract
OBJECTIVE: To analyse the efficacy of short-course (SCRT) versus long-course radiotherapy/chemoradiation (LCRT) as a neoadjuvant modality for the management of lower rectal cancer (LRC). METHODS: A systematic review of the literature was undertaken. Selected trials were analysed to generate a summative outcome. RESULTS: Seven trials on the efficacy of SCRT versus LCRT as a neoadjuvant modality for LRC encompassing 1,675 patients were retrieved but only 2 randomized trials on 396 patients qualified for this review. In both the fixed and random effects models, LCRT and SCRT were associated with equal overall survival, tumour recurrence, perioperative complications, sphincter preservation rate and toxicity. CONCLUSIONS: SCRT and LCRT may be as effective as traditional LCRT in terms of overall survival, recurrence, perioperative complications, sphincter preservation and toxicity. Traditional neoadjuvant chemoradiation may continue to be used.
OBJECTIVE: To analyse the efficacy of short-course (SCRT) versus long-course radiotherapy/chemoradiation (LCRT) as a neoadjuvant modality for the management of lower rectal cancer (LRC). METHODS: A systematic review of the literature was undertaken. Selected trials were analysed to generate a summative outcome. RESULTS: Seven trials on the efficacy of SCRT versus LCRT as a neoadjuvant modality for LRC encompassing 1,675 patients were retrieved but only 2 randomized trials on 396 patients qualified for this review. In both the fixed and random effects models, LCRT and SCRT were associated with equal overall survival, tumour recurrence, perioperative complications, sphincter preservation rate and toxicity. CONCLUSIONS:SCRT and LCRT may be as effective as traditional LCRT in terms of overall survival, recurrence, perioperative complications, sphincter preservation and toxicity. Traditional neoadjuvant chemoradiation may continue to be used.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber Journal: Int J Radiat Oncol Biol Phys Date: 1999-07-15 Impact factor: 7.038
Authors: Vincenzo Valentini; Bengt Glimelius; Bruce D Minsky; Eric Van Cutsem; Hanry Bartelink; Regina G H Beets-Tan; Jean-Pierre Gerard; Paris Kosmidis; Lars Pahlman; Aurelio Picciocchi; Phil Quirke; Joel Tepper; Maurizio Tonato; Cornelius J Van de Velde; Numa Cellini; Paolo Latini Journal: Radiother Oncol Date: 2005-09 Impact factor: 6.280
Authors: J F Bosset; G Calais; A Daban; C Berger; L Radosevic-Jelic; P Maingon; E Bardet; M Pierart; A Briffaux Journal: Eur J Cancer Date: 2004-01 Impact factor: 9.162